Bayer's blood thinner fails Eliquis test, sinking phase 3 trial and denting $5B sales forecast

Bayer’s plans to turn asundexian into a 5 billion euro ($5.5 billion) a year medicine have taken a hit. The factor XIa inhibitor had “inferior efficacy” to Bristol Myers Squibb and Pfizer’s Eliquis in a phase 3 trial, prompting Bayer to stop the study early while continuing to advance the asset in another indication.